| Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial.Lancet Oncol | PMID 42945979无 PMCID | 2026-Oct-27 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.Lancet | PMID 42933459无 PMCID | 2026-Oct-26 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study.Ann Oncol | PMID 42933636PMC13718749 | 2026-Oct-26 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Prognostic associations between patient-reported outcomes and progression-free and overall survival in advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 TAP score ≥ 5%: results from the RATIONALE-305 trial.Qual Life Res | PMID 42927580PMC13696556 | 2026-Oct-25 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study.Ann Oncol | PMID 42927853无 PMCID | 2026-Oct-25 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).Ann Oncol | PMID 42927854无 PMCID | 2026-Oct-25 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.Ann Oncol | PMID 42927855无 PMCID | 2026-Oct-25 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.Ann Oncol | PMID 42927856无 PMCID | 2026-Oct-25 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.N Engl J Med | PMID 42929675无 PMCID | 2026-Oct-25 | 0.99 | Eligible primary Phase 3 randomized oncology drug trial with a time-to-event primary endpoint and reported original results. | 待处理 |
| Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.N Engl J Med | PMID 42929693无 PMCID | 2026-Oct-25 | 0.98 | Eligible original Phase 3 randomized drug trial report in advanced NSCLC with time-to-event primary endpoint and reported Kaplan-Meier/hazard-ratio results. | 待处理 |
| Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.N Engl J Med | PMID 42929694无 PMCID | 2026-Oct-25 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| COMPANION-002: A Randomized Phase II/III Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-Line Therapy in Patients With Advanced Biliary Tract Cancer.J Clin Oncol | PMID 42920414无 PMCID | 2026-Oct-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| ENZARAD (ANZUP 1303): Phase III Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.J Clin Oncol | PMID 42921729无 PMCID | 2026-Oct-24 | 0.98 | Eligible original Phase III randomized oncology drug trial reporting a primary time-to-event efficacy result. | 待处理 |
| Short-Course Ruxolitinib Initiated at Neutrophil Engraftment for Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Randomized, Open-Label, Controlled Phase II Trial.Transplant Cell Ther | PMID 42926045无 PMCID | 2026-Oct-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW.Ann Oncol | PMID 42926106无 PMCID | 2026-Oct-24 | 0.99 | Eligible as an original formal-result Phase III randomized oncology trial with drug intervention and time-to-event efficacy endpoints. | 待处理 |
| A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.Ann Oncol | PMID 42926107无 PMCID | 2026-Oct-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.Ann Oncol | PMID 42926108无 PMCID | 2026-Oct-24 | 0.97 | Eligible: phase III randomized oncology drug trial reporting final overall survival time-to-event results. | 待处理 |
| Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).Ann Oncol | PMID 42926109无 PMCID | 2026-Oct-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol | PMID 42926111无 PMCID | 2026-Oct-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.N Engl J Med | PMID 42929692无 PMCID | 2026-Oct-24 | 0.98 | This is an original Phase 3 randomized oncology trial of drug interventions with time-to-event primary and key secondary efficacy endpoints, reporting formal results. | 待处理 |
| Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.N Engl J Med | PMID 42929702无 PMCID | 2026-Oct-24 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small-cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study.Ann Oncol | PMID 42918419无 PMCID | 2026-Oct-23 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Neoadjuvant nivolumab plus gemcitabine-cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine-cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial.Ann Oncol | PMID 42918420无 PMCID | 2026-Oct-23 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.Ann Oncol | PMID 42918422无 PMCID | 2026-Oct-23 | 0.99 | Eligible original Phase III randomized oncology drug trial reporting a primary time-to-event efficacy endpoint (EFS) with hazard ratios and Kaplan-Meier-type survival estimates. | 待处理 |
| Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.Ann Oncol | PMID 42918423无 PMCID | 2026-Oct-23 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.Ann Oncol | PMID 42918424无 PMCID | 2026-Oct-23 | 0.95 | Eligible updated Phase III randomized drug trial report in human prostate cancer with OS/rPFS time-to-event efficacy results. | 待处理 |
| Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.JAMA | PMID 42925007PMC13695078 | 2026-Oct-23 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.N Engl J Med | PMID 42734213无 PMCID | 2026-Oct-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268).Radiother Oncol | PMID 42913944无 PMCID | 2026-Oct-22 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer.Nat Commun | PMID 43052301PMC13782546 | 2026-Oct-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.J Clin Oncol | PMID 42777180PMC13682723 | 2026-Oct-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of KRAS-Targeted Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: An Updated Systematic Review and Meta-Analysis of Pooled Proportions.Am J Clin Oncol | PMID 42956271无 PMCID | 2026-Oct-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.N Engl J Med | PMID 42874102无 PMCID | 2026-Oct-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Interpretable Prediction of Lymphopenia Following Neoadjuvant Chemoradiotherapy for rectal Cancer: An Analysis of the ARISTOTLE randomized phase 3 Trial.Clin Oncol (R Coll Radiol) | PMID 43019770无 PMCID | 2026-Oct-14 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Health-related Quality of Life With Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL: Phase 3 SUNMO Trial.Clin Lymphoma Myeloma Leuk | PMID 42971868无 PMCID | 2026-Oct-12 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO.Clin Lymphoma Myeloma Leuk | PMID 42998919无 PMCID | 2026-Oct-11 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Strategy Integrating Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors for Oligometastatic Non-Small Cell Lung Cancer: A Narrative Review.Cancer Res Treat | PMID 42845030无 PMCID | 2026-Oct-08 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Contemporary Chemotherapy Benchmarks for Molecularly Defined Advanced NSCLC: Reconstructed Individual Patient-Level Data of 22 Randomized Trials.Lung | PMID 42842004PMC13645942 | 2026-Oct-07 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC.Target Oncol | PMID 42830371无 PMCID | 2026-Oct-04 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.Lancet | PMID 42702214无 PMCID | 2026-Oct-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.Leukemia | PMID 42827117无 PMCID | 2026-Oct-02 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.Cancer | PMID 42764731PMC13591201 | 2026-Oct-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Giredestrant plus Everolimus in Advanced Breast Cancer.N Engl J Med | PMID 42814929PMC13674676 | 2026-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704.Int J Radiat Oncol Biol Phys | PMID 42822544PMC13641179 | 2026-Oct-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Ultra-hypofractionated versus conventional chemoradiation for newly diagnosed glioblastoma: Survival and toxicity results of a multicenter randomized trial.Radiother Oncol | PMID 42570798无 PMCID | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.Int J Clin Oncol | PMID 42579028PMC13615008 | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel.Eur Urol Oncol | PMID 42595654无 PMCID | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Induction TPF versus adjuvant PF after CCRT in locally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled phase III clinical trial.Radiother Oncol | PMID 42604670无 PMCID | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.Br J Haematol | PMID 42608172无 PMCID | 2026-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.Lung Cancer | PMID 42636548无 PMCID | 2026-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |